Clinical trial

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

NCT01957007

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-09-01

PhasePHASE1

Study timeline

Study start (unknown)2013-09-01Date precision: month

Registry last updated2020-09-09

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Solid Tumorsunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

vantictumabDRUG

Sponsors & collaborators

OncoMed Pharmaceuticals, Inc.lead sponsor

Mapped research locations

ClevelandOhio, United States1 AuroraColorado, United States1 BuffaloNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01957007 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.